Semler Scientific under investigation by Faruqi & Faruqi for securities fraud.
ByAinvest
Wednesday, Oct 8, 2025 10:06 am ET1min read
SMLR--
The complaint alleges that Semler Scientific discussed potential violations of the False Claims Act in hypothetical terms without disclosing an ongoing DOJ investigation. The company's public statements were found to be false and materially misleading during the class period. The lawsuit claims that investors suffered damages as a result of these misrepresentations [2].
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Semler Scientific. The firm encourages investors who suffered losses to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights [2].
The deadline to seek the role of lead plaintiff in the federal securities class action is October 28, 2025 [2]. Investors who purchased shares during the specified period are encouraged to contact the firm to discuss their participation in the lawsuit.
Faruqi & Faruqi LLP is investigating potential claims against Semler Scientific, a biotechnology company. The investigation focuses on potential securities law violations between March 10, 2021, and April 15, 2025. Investors who suffered losses in Semler Scientific are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. The deadline to seek the role of lead plaintiff is October 28, 2025.
Semler Scientific, Inc. (NASDAQ: SMLR), a biotechnology company, is facing a class action lawsuit alleging securities law violations. The lawsuit, filed on behalf of investors who purchased shares during the period from March 10, 2021, to April 15, 2025, accuses the company of making false and misleading statements and failing to disclose a material investigation by the U.S. Department of Justice (DOJ) into violations of the False Claims Act [2].The complaint alleges that Semler Scientific discussed potential violations of the False Claims Act in hypothetical terms without disclosing an ongoing DOJ investigation. The company's public statements were found to be false and materially misleading during the class period. The lawsuit claims that investors suffered damages as a result of these misrepresentations [2].
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Semler Scientific. The firm encourages investors who suffered losses to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights [2].
The deadline to seek the role of lead plaintiff in the federal securities class action is October 28, 2025 [2]. Investors who purchased shares during the specified period are encouraged to contact the firm to discuss their participation in the lawsuit.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet